Author’s note: The current U.S. political environment is unsuitable for implementing a system permitting patients to use late-stage experimental drugs if they choose. That environment would improve if ...
Excerpted from the booklet More Choices, Better Health: Free to Choose Experimental Drugs, by Bartley J. Madden–the last in a several-part series. The complete ...
The Consumer Financial Protection Bureau (CFPB) has released its latest supervision report outlining the illegal practices uncovered by the Bureau’s examiners in the first four months of 2015. The ...
In biotechnology, timing is everything. Whether advancing a novel therapy or scaling a platform, companies often reach a pivotal point: go public or sell. Increasingly, biotech executives are choosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results